SALT LAKE CITY,
March 22, 2022
/PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the
"Company"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today that it will present at the 3rd Annual
MarketsandMarkets Infectious Disease Diagnostics and Molecular
Diagnostics Conference, held March 23-24,
2022, in London,
England.
Co-Diagnostics CEO Dwight Egan
will be presenting on the Company's YourTest™ PCR
at-home/point-of-care testing device to the international audience
at 14:00 GMT on March 23rd. The Company will also be hosting a
booth for conference participants displaying its PCR product
offerings. Products built on the YourTest PCR platform are subject
to regulatory review and are not currently for sale.
The MarketsandMarkets Infectious Disease Diagnostics and
Molecular Diagnostics Conference is expected to witness an
overwhelming participation of leading healthcare and industry
decision makers who are amplifying the future of diagnostics, with
key highlights that include molecular diagnostic techniques for
medical viruses, advances in at-home and point-of-use testing for
Covid-19 and beyond, point of care testing and recommendations for
future emerging outbreaks, the impact of the Covid-19 pandemic on
diagnostic innovation for infectious disease, and portable
point-of-care testing systems and increasing global access to care,
among others.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a
state-of-the-art diagnostics technology. The Company's technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA) that are
subject to a number of risks and uncertainties. Risks and
uncertainties that may cause such differences include, among other
things: our products may not prove to be as effective as other
products currently being commercialized or to be commercialized in
the future by competitors; risks inherent in manufacturing and
scaling up to commercial quantities while maintaining quality
controls; the uncertainties inherent in new product development,
including the cost and time required to gain regulatory clearance
for such product and to commercialize such product(s);and, market
acceptance of our products once commercialized. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management's current estimates, projections,
expectations, and beliefs. There can be no assurance that any of
the anticipated results will occur on a timely basis or at all due
to certain risks and uncertainties, a discussion of which can be
found in the Risk Factors disclosure in our Annual Report on Form
10-K, filed with the Securities and Exchange Commission (SEC) on
March 25, 2021, and in our other
filings with the SEC. The Company does not undertake any obligation
to update any forward-looking statement relating to matters
discussed in this press release, except as may be required by
applicable securities laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-marketsandmarkets-conference-on-march-23-24-in-london-england-301507640.html
SOURCE Co-Diagnostics